FDA Approves Finerenone (Kerendia) for Heart Failure with Ejection Fraction of 40% or More
Finerenone gains FDA approval for heart failure treatment, offering new hope for patients with reduced ejection fraction and improving care options.
Related Articles
Kidney Compass: NUDGE-CKD and the Power of Pragmatic Trials
Host Brendon Neuen is joined by guests Tor Biering-Sørensen and Kristoffer Skaarup to discuss NUDGE-CKD and implementation trial design.
Insights on Deucravacitinib for Psoriasis During Expert Consensus Panel, with Hassan Hamade, MD
This interview with Hamade highlights some of the most notable takeaways regarding deucravacitinib’s safety among patients with psoriasis.
Insights on Deucravacitinib for Psoriasis During Expert Consensus Panel, with Hassan Hamade, MD
This interview with Hamade highlights some of the most notable takeaways regarding deucravacitinib’s safety among patients with psoriasis.
HCPLive Clinical Forum Events
Sign up for upcoming Clinical Forum events for Oncologists. Available virtually or in-person | HCPLive
FDA Approves Finerenone (Kerendia) for Heart Failure with Ejection Fraction of 40% or More
Finerenone gains FDA approval for heart failure treatment, offering new hope for patients with reduced ejection fraction and improving care options.
HCPLive Clinical Forum Events
Sign up for upcoming Clinical Forum events for Oncologists. Available virtually or in-person | HCPLive
Skin of Color Savvy: News Update—Consulting with Physicians Outside of Dermatology
This July 15, 2025 SOCS News Update highlights Regine Mathieu, MD’s experiences and views on collaboration opportunities.
Liver Lineup: Progress, Policy, and Barriers in Hepatitis C Elimination
Hosts Kimberly Brown and Nancy Reau discuss policy, clinical, and structural milestones enabling HCV elimination efforts and critical gaps impeding progress.
Skin of Color Savvy: News Update—Consulting with Physicians Outside of Dermatology
This July 15, 2025 SOCS News Update highlights Regine Mathieu, MD’s experiences and views on collaboration opportunities.
Diabetes Dialogue: BELIEVE, GLP-1/GIP Agonists, and CATALYST-2 Results at ADA 2025
Isaacs and Bellini discuss 3 more of the most impactful trials presented at the 85th annual American Diabetes Association conference in part 2 of this…